Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells

Toxicology Letters
Majorie B M van DuursenMartin van den Berg

Abstract

Cytochrome P450c17 (CYP17) has been linked to various hormone-related diseases, including breast cancer, thus being a potential target for cancer chemoprevention. We studied the naturally occurring phytochemical enterolactone (ENL) and 13 VIOXX-related lactone derivatives (CRI-1 to CRI-13) for their effects on CYP17 activity and expression and on cell cycle status in the human H295R adrenocorticocarcinoma cell line. Of the tested compounds, only CRI-3, -7, -10 and -12 showed to be inhibitors of CYP17 activity in H295R cells. This inhibition was not due to decreased mRNA expression, but was apparently caused by post-translational modification of the CYP17 enzyme. The MAPK kinase (MEK) inhibitor PD98059 induced CYP17 activity by 24%, while co-incubation of the CRI-s with PD98059, reduced CYP17 activity even further than the reduction caused by the CRI-s alone. In addition, CRI-3, -7, -10 and -12 arrested the cell cycle in the G(2)/M phase. The structure-activity similarities of the CRI-s with known micro-tubule binding agents strongly suggest that cell cycle arrest is a result of interaction with tubulin. We conclude that the proposed cancer chemopreventive actions of ENL are not mediated through interaction with CYP17 or cell cy...Continue Reading

References

Jan 1, 1985·The Journal of Applied Bacteriology·S P BorrielloA M Lawson
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·B C ChungW L Miller
Mar 1, 1981·Journal of Steroid Biochemistry·K Li, J B Adams
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L H ZhangW L Miller
Apr 1, 1995·British Journal of Cancer·J A WoodsA T McGown
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoE Hamel
May 8, 1998·Toxicology and Applied Pharmacology·M SekharamJ Wu
Jul 31, 1998·The British Journal of Nutrition·S A BinghamA Coward
Mar 17, 2000·The Journal of Clinical Endocrinology and Metabolism·A Biason-LauberM Zachmann
Feb 9, 2002·European Journal of Endocrinology·Cristina PucheAnna Meseguer
Jul 4, 2002·Nutrition and Cancer·G Murillo, R G Mehta
Jul 11, 2002·The Lancet Oncology·Herman Adlercreutz
Aug 31, 2002·Mutagenesis·Heather Spencer FeigelsonBrian E Henderson
Oct 9, 2002·The Journal of Nutrition·Susan E McCannPeter G Shields
Dec 31, 2002·The Journal of Biological Chemistry·Marion B Sewer, Michael R Waterman
Feb 27, 2003·Breast Cancer Research and Treatment·P H M PeetersD E Grobbee
Aug 14, 2003·The Journal of Clinical Endocrinology and Metabolism·Christa E FlückRichard J Auchus
Jan 30, 2004·The American Journal of Clinical Nutrition·Lital Keinan-BokerPetra H M Peeters
Mar 24, 2004·The British Journal of Nutrition·Pamela J Magee, Ian R Rowland
Apr 8, 2004·International Journal of Cancer. Journal International Du Cancer·Jakob LinseisenUNKNOWN German Case-Control Study
Apr 16, 2004·Breast Cancer Research : BCR·Jane L Limer, Valerie Speirs
Apr 20, 2004·Critical Reviews in Oncology/hematology·Sandra Timm Pearce, V Craig Jordan
Jun 10, 2004·Microbiology and Molecular Biology Reviews : MMBR·Philippe P Roux, John Blenis
Jun 16, 2004·CA: a Cancer Journal for Clinicians·Anne S TsaoWaun Ki Hong
Sep 21, 2004·Annual Review of Plant Biology·Richard A Dixon
Oct 19, 2004·Cancer Letters·Thambi Dorai, Bharat B Aggarwal
Jan 13, 2005·JAMA : the Journal of the American Medical Association·Carla H van GilsElio Riboli
Jan 15, 2005·Annals of the New York Academy of Sciences·Luigi CastagnettaGiuseppe Carruba
May 7, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Jennifer D Brooks, Lilian U Thompson
May 12, 2005·JAMA : the Journal of the American Medical Association·Bernhard Watzl
Jul 1, 2005·Breast Cancer Research : BCR·Emaculate Verla-TebitJenny Chang-Claude
Nov 11, 2005·Breast Cancer Research : BCR·Julian Little, Jacques Simard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.